Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

New hair loss treatments, including Breezula, VDPHL01, and PP405, are nearing Phase 3 trials, offering hope for effective solutions. Current treatments like finasteride and minoxidil remain effective, but early intervention is crucial.

The user shares their hair loss treatment routine, which includes topical minoxidil, botana oil, coconut moisturizer, derma stamping, derma rolling, 3% salicylic acid shampoo, and scalp massage. Suggestions include adding finasteride, switching to 2% ketoconazole shampoo, and using rosemary oil instead of botana oil.

Clascoterone 5% shows promising hair growth results but is criticized for high cost and unclear effectiveness compared to other treatments like finasteride. Glenmark is testing a combination of Clascoterone 7.5% and Minoxidil 5% in India.

Mixing finasteride with retinol for a topical solution to avoid irritation from minoxidil. Finasteride and ketoconazole shampoo help with itchiness.

Clascoterone 5% solution shows strong potential for hair growth, offering a new treatment for alopecia with minimal side effects. It blocks androgen receptors locally and may be available by late 2026 or early 2027.

The conversation discusses using liquid cetirizine as a topical treatment for hair loss. It mentions Minoxidil, finasteride, and RU58841 as other treatments.

The conversation is about making topical finasteride with stemoxydine, including questions on dosages, bulk preparation, and storage.

Pelage secured $120 million for PP405, a non-hormonal topical hair loss treatment, sparking debate on its potential as a breakthrough. Concerns about finasteride's side effects persist, with some suggesting alternatives like topical finasteride or dutasteride.

Pelage Pharmaceuticals raised $120M for their hair loss treatment, PP405, showing strong investor confidence despite limited data. There is skepticism about its efficacy and long-term effects compared to treatments like GT20029.

A user is creating a custom topical hair regrowth serum using minoxidil, bimatoprost, tretinoin, castor oil, and hyaluronic acid. They are also using dutasteride, oral minoxidil, and castor oil in their current regimen.

The user is using oral finasteride and minoxidil 2mg for hair loss and is considering adding a scalp serum with caffeine, but is concerned it might interfere with minoxidil. They seek advice on maintaining a hydrated, non-oily scalp.

Hair loss treatments Cosmerna, RU, and Pyri discussed. Cosmerna inhibits androgen receptors, but not 100%, so RU/Pyri can be used synergistically.

A user's humorous experience with using minoxidil to treat hair loss, which was met with laughter from other users.

PP405 is suspected to be a scam, with users doubting its legitimacy and effectiveness. Many recommend using proven treatments like finasteride and minoxidil.

Minoxidil, finasteride, and RU58841 are discussed as treatments for hair loss, with excitement around a new drug, PP405, and a reformulated oral minoxidil in trials. Concerns about cost, side effects, and long-term use are also mentioned.

The conversation is about choosing a topical antiandrogen for hair loss, with options including RU58841, CB0301, Pyrolutamide, Alfatradiol, and Fluridil. Users discuss their preferences and reasons for selecting specific treatments.

Cetirizine 10mg daily reduced hair shedding by 50% and lessened scalp itchiness. The user is considering long-term use for scalp inflammation and hair loss.

Pelage is developing a topical hair follicle stem cell therapy, PP405, for non-scarring alopecias like androgenetic alopecia, with Phase III trials planned and a potential market launch by 2027. The treatment may not require continuous use after initial regrowth.

The conversation discusses anticipation for CB-03-01, a potential new hair loss treatment that may be more effective and have a cleaner safety profile than finasteride. Users are hopeful but cautious, discussing current treatments like minoxidil, nizoral, and dermarolling, and the possibility of combining them with CB-03-01 for better results.

Clascoterone 5% solution showed a 539% improvement in hair count compared to placebo, but the actual increase in hair growth is minimal. Users express skepticism about the effectiveness of hair loss treatments.

A satirical post humorously discusses a fictional hair regrowth drug called PP405, with users joking about its effectiveness and bizarre presentation. The conversation includes humorous reactions and references to the absurdity of the content.

A user made a 70/30 ethanol/propylene glycol topical finasteride solution but noticed chunks at the bottom. The discussion focuses on this issue with the DIY hair loss treatment.

The conversation is about using a topical serum for hair loss with ingredients like finasteride and minoxidil, and the option to exclude retinoic acid and hydrocortisone due to concerns about long-term effects. One user prefers using only finasteride, avoiding minoxidil and retinoic acid, and plans to remove hydrocortisone in future orders.

A user is seeking a pharmacy to compound a topical solution containing Minoxidil, Finasteride, Alfatradiol, Melatonin, Latanoprost, and either RU58841 or Pyrilutamide. They prefer a professional compounding lab over DIY methods.

A 30-year-old man with hairline recession is considering using 1% Clascoterone cream on his hairline while awaiting a 5% Breezula product. He has been using oral Minoxidil for four years but stopped using Finasteride due to side effects.

The user experienced side effects with both oral and topical finasteride and is considering making their own hair loss treatment using CB-03-01 (Breezula) mixed with minoxidil due to fewer reported side effects. They plan to use a lower concentration than what was used in trials.

A compound called MTP3 from the Monoterpene family was found to be safe and highly effective at treating hair loss by inhibiting the FGF5 gene, but its identity is undisclosed for commercial reasons. No specific treatments like Minoxidil, finasteride, or RU58841 were discussed.